All News
Participation is Up! (1.31.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. We also have two call-in cases on "Ask Cush Anything".
Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?
Read ArticleAGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Read ArticleYoung Males and Future Risk of MSK and Chronic Diseases
A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes.
Celecoxib Lowers Colon Cancer Recurrence Risk
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib
Read ArticleProinflammatory Diet Increases Gout Risk
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.
Read ArticleInfectious Sacroiliitis
A large Chinese cohort study of patients with infectious sacroiliitis (SI) suggests that CT-guided biopsy of the sacroiliac joint is necessary to properly identify the infectious pathogen leading to SI.
Read ArticleAdalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Read ArticleWeak Data (1.24.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.
Read ArticleGetting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.
Do Rheumatologists Follow 2020 ACR Guidelines on Gout?
Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.
Functional Precision Medicine in Rheumatoid Arthritis
Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.
Read ArticleCardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
Read Article


